| |AUGUST 20248NEUROBO PHARMA INKS PACT WITH MTHERA PHARMA TO TREAT DIABETIC NEUROPATHYSANOFI RECEIVES DRUG REGULATOR APPROVAL TO MARKET RSV THERAPY IN INDIANeuroBo Pharmaceuticals, Inc., a biotech company in the clinical stage that specializes in addressing cardiometabolic diseases, revealed the completion of a unique licensing deal with MThera Pharma Co., Ltd. (MTHERA) has the rights to NB-01 for treating painful diabetic neuropathy.The agreement permits MTHERA to carry out research and clinical trials, including a possible phase 3 clinical trial in the United States and South Korea, towards the future marketing of NB-01. The financial details of the agreement were not made public."Finalizing this agreement for NB-01 is an important milestone for NeuroBo, reflecting our stated commitment to out-license our legacy assets in order to focus on the continued clinical development of DA-1726 and DA-1241," stated Hyung Heon Kim, president and chief executive officer of NeuroBo. "Based on the positive phase 2 efficacy results for NB-01 for diabetic neuropathy, we intend to develop it as a potential treatment for peripheral diabetes," stated Dr. Mi Won Sohn, chief executive officer of MTHERA. "Utilizing our SyMthomics platform technology, we can clearly identify the mechanism of action and active ingredients of NB-01 to assist in predicting its clinical efficacy as an innovative treatment, with the intent of advancing NB-01 into the next phase of clinical development. We are grateful to NeuroBo for the opportunity to further advance NB-01, and to potentially bring this promising therapy to patients in need". POSanofi, a pharmaceutical company from France, announced that the Central Drugs Standard Control Organization (CDSCO) in India has approved the marketing of their new treatment Beyfortus for newborns and infants with respiratory syncytial virus (RSV).Sanofi stated that Beyfortus has nirsevimab monoclonal antibody in a pre-filled injection for preventing lower respiratory tract disease (LRTD) in newborns and infants entering their first RSV season.It is also given to children up to 24 months old who are still at risk for serious RSV illness during their second RSV season, it stated. RSV is an extremely infectious virus that can result in severe respiratory illness in babies. Sanofi reports that 66 percent of infants contract RSV in their first year, and nearly all children are infected by age two."In addition to being the most common cause of LRTD such as bronchiolitis and pneumonia in infants, RSV is also a leading cause of hospitalization in infants worldwide, with most hospitalizations occurring in healthy infants born at term," the company said.Around 33 million instances of acute lower respiratory infections were recorded worldwide in 2019, resulting in over 3 million hospitalizations, with an estimated 26,300 in-hospital deaths of children under 5 years old.During March of 2017, Sanofi and leading pharmaeutical firm AstraZeneca disclosed a deal to collaborate on the advancement and distribution of Beyfortus. According to the agreement, AstraZeneca is responsible for development and manufacturing, while Sanofi handles commercialization and revenue tracking. POTOP STORIES
< Page 7 | Page 9 >